The sensitivities of CEA in diagnosing early stage and late stage CRC patients at 2.5 ng/ml were 54.7% and 77.8% and at 5 ng/ml were 26.4% and 50%, respectively, indicating that CEA showed a higher sensitivity in patients with higher stage CRC. This evidence concerns the gene CEACAM5 and colorectal carcinoma.